Enforcement is accelerating, and it now goes beyond letters
The FDA has issued waves of warning letters to online peptide sellers since December 2024, rejecting "research use only" defenses. In 2026, a drugmaker lawsuit and a federal criminal conviction followed.
The FDA posts its warning letters publicly. Read together, the letters to online peptide sellers since late 2024 tell a clear story: the agency doesn't accept "research use only" as a defense, and enforcement is picking up. This page records the major actions; we update it as new letters post.
What a warning letter is, and isn't
A warning letter is the FDA's formal notice that it believes a company is violating federal law. It isn't a court ruling or a final finding. Companies typically get 15 business days to respond, and the letters warn that uncorrected violations may lead to legal action, including seizure and injunction, without further notice.
The timeline
| Date | Action | What was cited |
|---|---|---|
| Dec 10, 2024 | Warning letters to Swisschems, Summit Research Peptides, and others | Semaglutide, retatrutide, and other GLP-1-class products; dosing protocols next to "research use only" disclaimers |
| Sep 9, 2025 | Letters to GLP-1 Solution and other compounded-GLP-1 sellers, part of a sweep reported at 50+ letters | Retatrutide; misleading claims about compounded drugs |
| Mar 31, 2026 | Letters to Gram Peptides, Prime Sciences, Pink Pony Peptides (Lovega LLC), PekCura Labs, and Mile High Compounds | Retatrutide, tirzepatide, cagrilintide, mazdutide; bacteriostatic water sold for reconstitution |
| Jun 17, 2026 | Letter to Wholesale Peptide | Injectable Prostamax and gonadorelin marketed as unapproved drugs |
| Aug 24, 2026 (posted Sep 1) | Letters to Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and Tex Peptides (TXP Innovations) | Semaglutide, tirzepatide, retatrutide, survodutide, mazdutide, SS-31, PT-141, tesamorelin, and a tesamorelin-ipamorelin blend |
Across these actions, retatrutide stands out: the FDA has cited it in more than 20 warning letters since December 2024. See our retatrutide explainer.
What the FDA looks at
The letters judge a seller by its whole website, not its disclaimers. Recurring evidence includes product descriptions that imply human benefits, dosing information, bacteriostatic water sold for preparing injections, and, in two August 2026 letters, on-site "peptide calculators." Our explainer on what "research use only" really means covers why the label doesn't help.
Beyond letters
Enforcement escalated in 2026:
- August 12, 2026: Eli Lilly, which makes Zepbound and is developing retatrutide, sued six sellers of retatrutide.
- September 18, 2026: A federal jury convicted a Texas man who ran the Pinned Aminos websites, which sold drugs labeled as "research compounds."
Why this matters if you're a buyer
Warning letters are a public record of sellers the FDA believes are marketing unapproved drugs. A seller's absence from this list doesn't mean it's legitimate; the FDA reviews only a fraction of websites. The safer path is products that are FDA-approved or legally compounded and prescribed by a licensed clinician. Check each peptide's status on our FDA tracker.
What this article is based on
Checked October 27, 2026. Primary FDA documents are listed first where available.
- Aminowire: FDA warning letters to peptide sellers, explained
- VialAudit: FDA peptide enforcement 2024–2026, letters and lawsuits
- Veloxpeps: FDA warning letters to five online peptide sellers (September 2026)
- PeptidesBeat: FDA warns online peptide sellers (September 2026)
- Mirror Plastic Surgery: Is buying peptides online safe? (FDA warning letter summary)
- Nootroholic: Peptide scams, raids and enforcement actions (2026)
About this content: The Peptide Verdict is an independent educational publication. Articles are researched and written with AI assistance, edited by our editorial team, and checked against the primary sources listed on each page. They are not reviewed by a medical professional and are not medical, legal, or pharmacy advice. Peptide regulations change quickly; always check the dates shown and confirm current rules. Talk to a licensed clinician before using any peptide or medication.